StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZFree Report) in a report issued on Saturday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

ENZ stock opened at $1.04 on Friday. The business has a 50 day moving average price of $1.12 and a 200 day moving average price of $1.12. Enzo Biochem has a fifty-two week low of $0.93 and a fifty-two week high of $1.50.

Enzo Biochem Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 15th will be given a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 38.46%. The ex-dividend date is Friday, November 15th.

Hedge Funds Weigh In On Enzo Biochem

Several large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares in the last quarter. XTX Topco Ltd increased its position in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares during the period. Geode Capital Management LLC increased its position in Enzo Biochem by 3.3% during the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after buying an additional 11,742 shares during the period. Finally, BBR Partners LLC acquired a new stake in shares of Enzo Biochem in the third quarter valued at approximately $112,000. Institutional investors and hedge funds own 36.90% of the company’s stock.

Enzo Biochem Company Profile

(Get Free Report)

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

See Also

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.